Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics reported initial first-in-human data from its Phase 0/1 HEAT trial of 177Lu-RAD202, a first-in-class HER2-targeted radiopharmaceutical therapy, in heavily pre-treated patients with advanced HER2-positive solid tumors. Data from the lowest 30 mCi dose cohort showed meaningful tumor uptake, especially in breast cancer lesions, and a favorable safety profile with only Grade 1–2 treatment-emergent adverse events and no dose-limiting toxicities or treatment discontinuations.
Organ-level radiation doses were within expected and clinically acceptable ranges, supporting continued dose escalation of 177Lu-RAD202, and the Data Safety and Monitoring Committee has cleared the program to advance to a higher 130 mCi dose cohort. The results, presented at the 2026 AACR Annual Meeting, mark an early but important milestone for Radiopharm’s HER2-targeted program and could strengthen the company’s position in the emerging field of radiopharmaceutical therapies for difficult-to-treat solid tumors if efficacy is confirmed at therapeutic dose levels.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical-stage biopharmaceutical company developing innovative oncology radiopharmaceuticals aimed at cancers with high unmet medical need. The company focuses on targeted theranostic agents, including proprietary single-domain antibody platforms, to diagnose and treat advanced solid tumors such as HER2-positive breast and other cancers.
Average Trading Volume: 3,605,009
Technical Sentiment Signal: Sell
Current Market Cap: A$74.43M
For detailed information about RAD stock, go to TipRanks’ Stock Analysis page.